Editorial Comment

Daniel D Joyce^{1

2}

Affiliations

¹ Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
² Early Career Editor, The Journal of Urology®.

Comment

Daniel D Joyce. J Urol. 2025 Feb.

. 2025 Feb;213(2):215.

doi: 10.1097/JU.0000000000004303. Epub 2024 Oct 30.

Daniel D Joyce^{1

2}

¹ Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
² Early Career Editor, The Journal of Urology®.

No abstract available

Comment on

Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION).
Prasad SM, Shishkov D, Mihaylov NV, Khuskivadze A, Genov P, Terzi V, Kates M, Huang WC, Louie MJ, Raju S, Burger B, Meads A, Schoenberg M. Prasad SM, et al. J Urol. 2025 Feb;213(2):205-216. doi: 10.1097/JU.0000000000004296. Epub 2024 Oct 24. J Urol. 2025. PMID: 39446087 Free PMC article. Clinical Trial.